Acute kidney injury is a serious condition characterized by a sudden decline in kidney function, which can result from various causes, including trauma, infections, or medications. The condition accounts for around 10-15% of hospital admissions, with prevalence in intensive care unit (ICU) patients rising to over 50%. There is a high unmet clinical need for better therapies to treat acute kidney injury, as current options, such as dialysis, often fail to address the underlying causes effectively. Further, the growing focus on early detection, preventive measures, and novel treatments is likely to support pipeline growth in the coming years, offering hope for improved patient outcomes.
The assessment section will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to acute kidney injury.
The acute kidney injury drug pipeline focuses on developing therapies targeting inflammation, oxidative stress, and cellular repair. These advancements aim to address the high unmet need for effective treatments, emphasizing early intervention and organ protection.
This product will be delivered within 3-5 business days.
Report Coverage
The Acute Kidney Injury Drug Pipeline Insight Report by the publisher gives comprehensive insights into acute kidney injury therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acute kidney injury. The acute kidney injury report assessment includes an analysis of over 100 pipeline drugs and 50+ companies. The acute kidney injury pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with acute kidney injury treatment guidelines to ensure optimal care practices.The assessment section will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to acute kidney injury.
Acute Kidney Injury Drug Pipeline Outlook
Acute kidney injury is a sudden loss of kidney function caused by reduced blood flow, direct kidney damage, or urinary obstruction. It often occurs due to severe infections, trauma, or nephrotoxic drugs. Acute kidney injury treatments include supportive care such as fluid management and electrolyte balancing. In severe cases, renal replacement therapy such as dialysis is used.The acute kidney injury drug pipeline focuses on developing therapies targeting inflammation, oxidative stress, and cellular repair. These advancements aim to address the high unmet need for effective treatments, emphasizing early intervention and organ protection.
Acute Kidney Injury Epidemiology
Acute kidney injury is a significant global health concern, affecting 14.7% to 31.5% of hospitalized patients. In the United States, its incidence has risen by 14% annually since 2001. The ISN 0by25 study reveals that 80% of acute kidney injury in low- and middle-income countries is community-acquired, with dehydration (46%) and hypotension (38%) as leading causes.Acute Kidney Injury Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of acute kidney injury drug candidates based on several segmentations, including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
By Route of Administration
- Oral
- Parenteral
- Others
Acute Kidney Injury - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total acute kidney injury clinical trials.Acute Kidney Injury Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the acute kidney injury pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for acute kidney injury.Acute Kidney Injury Clinical Trials Therapeutic Assessment - Competitive Dynamics
The acute kidney injury report insights include the profiles of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in acute kidney injury clinical trials:- Hope Biosciences
- Genentech, Inc.
- CalciMedica, Inc.
- Novartis Pharmaceuticals
- Alexion Pharmaceuticals, Inc.
- Rediscovery Life Sciences
- Arch Biopartners Inc.
- EnnovaBio
- Baxter Healthcare Corporation
Acute Kidney Injury Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for acute kidney injury. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of acute kidney injury drug candidates.Drug: Ravulizumab
The ARTEMIS study, sponsored by Alexion Pharmaceuticals, Inc., aims to evaluate the efficacy of a single dose of ravulizumab IV compared to a placebo in reducing the risk of AKI-related outcomes (MAKE) in chronic kidney disease patients undergoing non-emergent cardiac surgery with CPB. This Phase 3 trial, with an estimated 736 participants, is expected to conclude by February 2027.Drug: GDC-8264
The Phase II study, sponsored by Genentech, Inc., aims to evaluate the efficacy and safety of GDC-8264 in preventing cardiac surgery-associated acute kidney injury (AKI) and major adverse kidney events (MAKE90). With an estimated 404 participants, the study is set to begin on January 15, 2025, and is expected to conclude by November 15, 2027.Reasons To Buy This Report
The Acute Kidney Injury Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for acute kidney injury. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within acute kidney injury pipeline insights.Key Questions Answered in the Acute Kidney Injury - Pipeline Insight Report
- What is the current landscape of acute kidney injury pipeline drugs?
- Which companies/institutions are developing acute kidney injury emerging drugs?
- How many phase II drugs are currently present in the acute kidney injury pipeline drugs?
- Which company is leading the acute kidney injury pipeline development activities?
- What is the current acute kidney injury therapeutic assessment?
- What are the opportunities and challenges present in the acute kidney injury drug pipeline landscape?
- What is the efficacy and safety profile of acute kidney injury pipeline drugs?
- Which companies/institutions are involved in acute kidney injury collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in acute kidney injury?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Acute Kidney Injury
4 Patient Profile: Acute Kidney Injury
5 Acute Kidney Injury: Epidemiology Snapshot
6 Acute Kidney Injury: Market Dynamics
7 Acute Kidney Injury: Key Facts Covered
8 Acute Kidney Injury, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Acute Kidney Injury Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Acute Kidney Injury Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Acute Kidney Injury Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Acute Kidney Injury, Key Drug Pipeline Companies
